CoChat
Sign Up
Cited by 22Hair Growth and DisordersOcular Surface and Contact LensOcular Disorders and Treatments

Patient-Reported Outcomes of Bimatoprost for Eyelash Growth

Fagien, Steven, Walt, John G., Carruthers, Jean, Cox, Sue Ellen, Wirta, David, Weng, Emily, Beddingfield, Frederick C.·2013·Aesthetic Surgery Journal
DOI 10.1177/1090820x13495887
Open this paper in CoChat — free account

Abstract

BACKGROUND: Hypotrichosis of the eyelashes may negatively influence an individual's self-perception and appearance. Assessing the impact of treatment from a patient's perspective may be particularly relevant in trials of aesthetic agents. Once-daily dermal (topically applied) administration of bimatoprost ophthalmic solution 0.03% has been associated with increased eyelash prominence (ie, length, thickness, darkness). OBJECTIVES: The authors assess patient-reported outcomes (PRO) after treatment with bimatoprost for hypotrichosis of the eyelashes. METHODS: In this multicenter, double-masked, randomized, vehicle-controlled, parallel clinical trial, 4 PRO questionnaires were distributed to 278 patients (bimatoprost [n = 137] and vehicle [n = 141]). The primary PRO questionnaire was the 23-item Eyelash Satisfaction Questionnaire (ESQ), which measured satisfaction in 3 domains: length, fullness, and overall satisfaction (LFOS); confidence, attractiveness, and professionalism (CAP); and impact on daily routine (DR). RESULTS: By week 16, the bimatoprost group reported significantly greater improvements from baseline on all ESQ items (P ≤ .0433). These improvements were sustained through the 4-week posttreatment study visit. Patient satisfaction was significantly greater in the bimatoprost group than in the vehicle group for all 3 domains: LFOS (weeks 8-20; P ≤ .0052), CAP (weeks 12-20; P < .0001), and DR (weeks 16 and 20; P ≤ .01). CONCLUSIONS: The bimatoprost group reported significantly greater levels of positive patient outcomes and satisfaction than the vehicle group across all 23 questions and all 3 domains of the primary PRO questionnaire. These results support the effectiveness, as measured by objective measures and PRO, of once-daily bimatoprost ophthalmic solution 0.03% at producing more prominent eyelashes in adults.

Integrity signals

Registry

Crossref · 10.1177/1090820x13495887

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Moses, 1970, The eyelids, 1

Cited by

Sorted by citations

Related

Authors
Fagien, S., Walt, J. G., Carruthers, J., Cox, S. E., Wirta, D., Weng, E., & Beddingfield, F. C.
Affiliations
  • Allergan (United States) (US)
  • University of British Columbia (CA)
  • University of North Carolina at Chapel Hill (US)
  • University of California, Los Angeles (US)
Corresponding author
Fagien, Steven
ORCID
Venue
Aesthetic Surgery Journal
Publisher
Oxford University Press (OUP)
Published
2013-08-01
Volume
33
Issue
6
Pages
789-798
ISSN
  • 1090-820X (ISSN-L)
  • 1527-330X
DOI
10.1177/1090820x13495887
OpenAlex
W2065778774
Cited by
22
References
22
Citations by year
2025: 1 · 2024: 2 · 2023: 3 · 2022: 1 · 2021: 1 · 2019: 3 · 2018: 2 · 2017: 3 · 2016: 1 · 2015: 2 · 2014: 2
FWCI
1.85
Type
journal article
Language
en
Open access
closed
Locations
  • Aesthetic Surgery Journal (publishedVersion)
  • PubMed (publishedVersion)
Funders
Allergan
Topics
  • Health Sciences › Medicine › Urology › Hair Growth and Disorders
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Ocular Surface and Contact Lens
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Ocular Disorders and Treatments
Keywords
bimatoprost, eyelash growth, patient-reported outcomes, patient satisfaction, eye drops, cosmetic procedures
MeSH terms
Bimatoprost, Administration, Topical, Adult, Aged, Amides, Body Image, Canada, Cloprostenol, Double-Blind Method, Eyelashes, Female, Humans, Hypotrichosis, Male, Middle Aged, Ophthalmic Solutions, Surveys and Questionnaires, Self Concept, Time Factors, United States, Treatment Outcome, Patient Satisfaction, Cost of Illness, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review